New strategies and approaches needed to cope with growing burden of brain diseases

5th Congress of the European Academy of Neurology

(Oslo, Monday, 1 July, 2019) New strategies for preventing and coping with the burden of brain diseases were outlined today at the 5th EAN Congress.

Prevention of brain diseases, the provision of equal treatment, follow-up and rehabilitation, as well as increased research and expertise, is vital in providing patients with optimal outcomes.”

— Professor Anne Hege Aamodt

OSLO, NORWAY, June 30, 2019 /EINPresswire.com/ — Professor Anne Hege Aamodt, President of the Norwegian Neurological Association, presented The Norwegian Brain Health Strategy 2018-2024 to attendees at the congress. Norway are the first country in Europe to launch a national brain health strategy, which has four overarching aims:

1. Good lifelong brain health, prevention and quality of life
2. The provision of user-centred care, as well as support for relatives
3. The organisation of holistic care from multi-disciplinary teams
4. Ensuring adequate knowledge and quality through research and innovation

Brain diseases now account for 10% of the global burden of disease. Dementia, one of the most common brain diseases, now affects around 50 million people worldwide with 10 million new cases every year. By 2030, it’s estimated that the number of people living with dementia will reach 82 million and this is expected to increase to 152 million by 2050.

“Brain diseases affect a wide range of people in all stages of life and, as people are living for longer, greater numbers now live with a range of brain diseases”, explained Professor Aamodt. “Prevention of brain diseases, the provision of equal treatment, follow-up and rehabilitation, as well as increased research and expertise, is absolutely vital in providing patients with optimal outcomes. This strategy will help to facilitate this for a number of brain diseases, including dementia, multiple sclerosis, Parkinson’s and stroke-related conditions.”

Initiatives outlined in the plan are now underway, which include the funding of a €20 million National Clinical Research Centre devoted to the clinical treatment of severe diseases such as MS, dementia and amyotrophic lateral sclerosis (ALS). In addition, the Norwegian Research Council will also receive an additional €5 million for strengthening research and innovation in neurological conditions.

The Norwegian Neurological Association and the Norwegian Directorate of Health are working to action further objectives outlined in the plan, which is being seen as a model template for other European countries to follow.

Professor Aamodt adds, “We believe that this national strategy should be replicated and implemented across Europe, tailored for each country. The continent will undergo major societal transformations, such as the ageing population, that will impact on brain diseases and health services must adapt to these changes.”

Following the launch of the Norwegian Brain Health Strategy, EAN and European Federation of Neurological Associations (EFNA) are also calling for a European Brain Health Plan raise public awareness of brain diseases, lobby governments and integrate the best science to improve outcomes for both patients and society.

Also at EAN 2019: Focusing on the burden of stroke and dementia

Professor Vladimir Hachinski, world-renowned stroke expert, stressed during the EAN Congress that stroke accounts for 42% of neurological disease, compared to 10% for dementia and that many cases of dementia could be prevented by preventing stroke.

Professor Hachinski said the quest to find a cure for Alzheimer’s in the past 40 years had focused on the amyloid/tau plaque hypothesis, but although this research had improved understanding of the dementia process, this ‘monorail’ approach had so far failed to yield a single disease-modifying drug.

Professor Hachinski stated “The good news is that stroke is 90% potentially preventable through the control of risk factors. Stroke and dementia share the same treatable risk factors and their control is associated with a decrease in stroke and some dementias. Additionally, intensive control of risk factors and enhancement of protective factors improve cognition.”

“Anticoagulation treatment of atrial fibrillation patients decreases their chance of developing dementia by 48 %. Preliminary data suggests that treating blood pressure to a target of 120mmHg systolic, compared to a target of 140mmHg, decreases the chances of mild cognitive impairment by 19 %.”

Professor Hachinski said neurological disorders are now responsible for the largest number of disability-adjusted life years (DALYs – a combined index of early mortality and years spent in disability). He added that the introduction of a stroke strategy in Ontario, Canada, which included building stroke units, stroke prevention clinics and campaigns to control risk factors, helped decrease the number of strokes by 32% over 12 years, with a 7% reduction in the incidence of dementia.

He stressed that whilst advancing age, genetic factors and family history couldn’t be changed, many other risk factors for stroke could be modified with physical activity, antihypertensive drugs, following a Mediterranean diet, an active lifestyle and taking statins to lower cholesterol.

Professor Hachinski concluded: “Neurological disorders represent the leading cause of DALYs. More than half result from stroke and dementia, which are both preventable to different degrees. We need new vistas and approaches to grasp the opportunity of preventing stroke and some dementias, beginning now.”

ENDS

Notes to Editors:

Press Enquiries:

For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at press@ean.org or call +44 (0) 7732 499170.

About the Experts:

Professor Anne Hege Aamodt is the President of the Norwegian Neurological Association
Professor Vladimir Hachinski is a Professor of neurology at Western Ontario University, Ontario, Canada

EAN – The Home of Neurology:

The European Academy of Neurology (EAN) is Europe’s home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. This year, EAN celebrates its fifth year of fostering excellence in European neurology.

References:

1. EAN/EFNA – Norwegian Brain Strategy: a plan to strengthen brain health in Europe. 5TH European Academy of Neurology Congress, Oslo, Norway
2. The Global Burden of Disease Study 2017 ( 2018) Lancet 32: 10159: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32279-7/fulltext
3. World Health Organisation, Dementia: https://www.who.int/news-room/fact-sheets/detail/dementia
4. Friberg L et al(2018). Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J 39;453-460 https://www.ncbi.nlm.nih.gov/pubmed/29077849
5. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia. A randomized clinical trial. (2019) JAMA 321: 553-561.
6. Sposato LA, Kapral MK, et al. (2015) Declining Incidence of stroke and dementia: coincidence or prevention opportunity? JAMA Neurol 72: 1529-1531. https://www.ncbi.nlm.nih.gov/pubmed/26658969

Luke Paskins
European Academy of Neurology (EAN)
+44 7732 499170
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Statin use reduces mortality and stroke risk in dementia patients, new study shows

5th Congress of the European Academy of Neurology

(Oslo, Monday, 01 July, 2019) Use of statins is significantly associated with a reduction in the risk of mortality in dementia patients, research has shown.

Our results are encouraging and suggest that patients with dementia benefit from statins to a similar extent than patients without dementia.”

— Dr Sara Garcia-Ptacek

OSLO, NORWAY, June 30, 2019 /EINPresswire.com/ — The study, which analysed 44,920 Swedish dementia patients from the Swedish Dementia Registry between 2008-2015, found users of statins had a 22% lower risk of all-cause death compared to matched non-users.

The research, presented today at the 5th EAN Congress, also demonstrated that statin users had a 23% reduction in the risk of stroke, which is three times more likely in patients with mild dementia and seven times more likely in those with severe dementia.

The protective effect of statins on survival were strong for patients younger than 75 years (27% reduction) and in men (26% reduction) but women and older patients also benefited (17% and 20% reduction respectively). Patients with vascular dementia – the second most common type of dementia after Alzheimer’s disease – also saw a 29% lower mortality risk.

“Survival in patients in dementia is variable, and previous studies have identified many factors associated with survival and risk of stroke in these patients”, commented first author Bojana Petek, MD, from the University Medical Center Ljubljana, Slovenia and the Karolinska Institutet, Sweden. “However, the effect of statins on these two outcomes is not clear. The aim of this study was to analyse the association between the use of statins on the risk of death and stroke in patients diagnosed with dementia.”

Commenting on their research, lead author Dr Sara Garcia-Ptacek from the Karolinska Institutet, Sweden, stated, “This is a cohort study, which means patients were not randomized to a treatment like they would be in a clinical trial. For this reason, we can only show an association, and not definitely prove that statins caused this decline in mortality. However, our results are encouraging and suggest that patients with dementia benefit from statins to a similar extent than patients without dementia.”

Affecting around 10 million people in Europe, dementia is the leading cause of dependency and disability among older people across the continent4. The number of cases is expected to double by 2030, largely due to the ageing population. The prevalence of dementia increases exponentially with age, affecting 5% of the population over 65, and up to 50% by 90 years of age.

ENDS

Notes to Editors:

Press Enquiries:

For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at press@ean.org or call +44 (0) 7732 499170.

About the Expert:

Bojana Petek, MD, is from Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden and the Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.

Dr. Sara Garcia-Ptacek, the Senior Author, is from the Division of Clinical Geriatric, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Sweden.

EAN – The Home of Neurology:

The European Academy of Neurology (EAN) is Europe’s home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. This year, EAN celebrates its fifth year of fostering excellence in European neurology and will bring together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe.

In Oslo, Norway, from June 29 to July 2, there will be an exchange of knowledge and promotion of best practice, with a focus on the main theme of neuroinflammation. The EAN Congress will also cover all neurological diseases and disorders, including the big 7: epilepsy, stroke, headache, multiple sclerosis, dementia, movement disorders, neuromuscular disorders.

References:

1. Statins, risk of death and stroke in patients with dementia – a registry-based study. Petek B, Villa-Lopez M, Winblad B, Kramberger MG, von Euler M, Xu H, Eriksdotter M, Garcia-Ptacek S, presented at the 5th Congress of International Neurology in Oslo.
2. The Swedish Dementia Registry (SveDem): www.svedem.se
3. Journal of Internal Medicine. 2017. Management of acute ischaemic stroke in patients with dementia. Available at: https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12588
4. WHO Europe, Dementia. Available at: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/areas-of-work/dementia

Luke Paskins
+44 7732 499170
email us here
European Academy of Neurology (EAN)
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Cowen Partners | Executive Search + Consulting Named "Top Executive Search Firm" for 2019

Cowen Partners Executive Search

For the three years in a row, Cowen Partners Executive Search has been named one of the nation's top executive search firms.

PORTLAND, OR, UNITED STATES, June 30, 2019 /EINPresswire.com/ — In the CATEGORIES of C-Suite Executive Search, Chief Financial Officer Executive Search, Healthcare, Financial Services – Banks & Credit Unions, and Executive Search for the REGIONS of the Pacific Northwest and West Coast, Cowen Partners | Executive Search + Consulting has been named a "Top Executive Search Firm" in 2017, 2018 and 2019.

“Our solutions are not limited to our known network and we are a search firm that prides itself on results and doing right by our clients, so it is nice to be recognized for our work.” said Shawn Cole, President and Founding Partner of Cowen Partners.

The list of "Top Search Firms" is meant to be a resource for companies and HR leaders seeking to understand the complexities of the executive search/ recruiting industry. Our research offers prospective employers a comprehensive look at the top executive search firms by offering resources, opinions, and rankings as a guide to helping you choose the best firm to meet your executive search needs. We do not accept payment from executive search firms for inclusion on our lists, we do accept input and feedback from firms on the list. We do not accept advertising from industry partners, vendors, suppliers, and employers.

Cowen Partners | Executive Search + Consulting works with leading organizations across the private and public sectors. Our scale, scope, and knowledge allow us to address problems that no one else can. We have deep strategic industry expertise as well as geographical reach, and we are passionate about taking on immense challenges that matter to our clients and their stakeholders.

For more information please contact Cowen Partners Executive Search at www.cowenpartners.com

Shawn Cole, President
Cowen Partners
+1 360-947-2804
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Announcing the Opening of Desert Gardens Assisted Living & Memory Care in Tucson: Luxury Living at Affordable Rates

Desert Gardens Assisted Living and Memory Care

Desert Gardens Assisted Living and Memory Care

Desert Gardens Offers Luxurious Accommodations

Luxurious Accommodations

This new assisted living home, located in the beautiful Foothills area, offers the support of compassionate, experienced caregivers.

We can provide you with peace of mind in the knowledge that your loved ones are being cared for like family.”

— Charles Loschiavo

TUCSON, AZ, USA, June 30, 2019 /EINPresswire.com/ — Desert Gardens Assisted Living is pleased to announce the opening of its brand new luxury home in the Foothills, offering a warm and inviting environment amidst spectacular mountain views. A ten-bed facility, the home is on a mission to enrich the lives of residents and their families and provide the best possible care in Tucson.

According to founder Charles Loschiavo, Desert Gardens is far superior to the average assisted living home because of the level of support it provides.

“Our caregivers are top notch,” says Loschiavo. “Each and every Desert Gardens employee was chosen for their caring nature, experience and professionalism. And we offer one-on-one care, which is really hard to find elsewhere.”

Loschiavo adds that Desert Gardens is fortunate to have Robin Duffy as their licensee house Manager and Administrator for her extensive experience in the industry and unparalleled care for seniors. Having successfully managed large facilities in Tucson, Robin was one of the individuals (along with Desert Gardens’ PRN Nurse) responsible for bringing the Eden alternative to the first facility in Arizona.

“Robin is well regarded in the community and has an immaculate reputation,” adds Loschiavo. We are very excited to have her fully on board!”
Loschiavo notes that although Desert Gardens only opened its doors in March of this year, it is already more than half full.

“We are proud of the fact that we are an affordable higher end assisted living home. Our residents are happy and well-cared for. Not surprisingly, we’ve had a lot of interest and don’t expect our remaining beds to stay empty for long!”

Desert Gardens offers a number of advantages and features:

• An individualized service plan for each resident
• Certified caregivers onsite 24 hours a day with a ratio of 5:1 residents to caregivers
• Assistance with dressing, eating, bathing, walking and personal hygiene
• Private and semi-private rooms
• “Open door” policy for visitors
• A variety of fun activities designed to engage the mind and body
• Three delicious meals per day; nutritious snacks always available
• Constant open communication with family members
• And a lot more.

In addition, Desert Gardens is one of the few homes in the area that adheres by the Eden Alternative. This revolutionary program was designed to improve the well-being of Elders and their care partners by transforming the communities in which they live and work and eliminate loneliness, helplessness, and boredom.
“We can provide you with peace of mind in the knowledge that your loved ones are being cared for like family,” concludes Loschiavo. “Give us a call or stop by – we’d be happy to give you a tour and answer any questions you might have.”

About Desert Gardens Assisted Living and Memory Care

Located at 3700 N River Hills Drive, Tucson, AZ, this comfortable home features luxurious, spacious rooms with breathtaking mountain views and highly-personalized, boutique care. Residents are provided with continuous care throughout the day and night by dedicated, highly trained caregivers.

Desert Gardens is currently accepting new residents. For more information, visit the website at www.desertgardensassistedliving.com.

Charles Loschiavo
Desert Gardens Assisted Living and Memory Care
+1 520-907-8833
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Yoga Kawa Offers Unique Puppy Yoga Experience to Corporate Clients

Corporate yoga class in progress

Corporate Yoga Class by Yoga Kaw

Yoga Kawa empowers businesses to succeed in building a productive & positive environment at work, &
designs classes based on individual goals of each company.

It is our mission to connect high-quality yoga teachers beyond yoga facilities and naturally integrate it into your daily and essential routine in life – workplace, sweet homes and special events.”

— Echo Wang

TORONTO, ONTARIO, CANADA, June 30, 2019 /EINPresswire.com/ — Ontario – If an employer is looking to create an activity that promotes collaboration amongst employees, corporate yoga service offered by Yoga Kawa is a top option. Yoga Kawa offers corporate clients a free consultation call to identify exactly what the company wants to accomplish, and then work together to design a well-integrated wellness program to achieve that goal.

Typically, corporate goals include but not limited to reducing healthcare cost, improving employee health, helping employees manage stress, as well as decreasing employee absenteeism. The corporate yoga program allows for a customizable program to suite the workplace schedule, culture, office layout, and budget. Yoga Kawa wants to provide their clients with the best possible experience, and keeps the goals of the client as the highest priority throughout their service.

Along with creating a fun class, the top goal of the corporate yoga class by Yoga Kawa is to cater to the needs of the employees, no matter the body type, gender, age, fitness or flexibility levels. The experienced teachers from Yoga Kawa focus on mobility, flexibility, relaxation, meditation, and many other unique needs that the employees may have.

Even though the company space is designed for the employees to perform work tasks, Yoga Kawa believes that yoga can be taught and practiced anywhere. Whether the session is conducted around conference tables, in the lobby, down a hallway, or even right by a group of desks, Yoga Kawa can work in any space.

In some cases, companies are looking for a unique yoga experience, and Yoga Kawa offers that in the form of puppy yoga classes. As employees focus on their practice and breathing, they get to experience the joy of watching puppies roam and play around. If certain employees do not seem interested in a traditional yoga class, puppy yoga is a definite way to get participants excited in your wellness program.

Yoga Kawa is a Canadian leader in corporate and condo yoga services. Yoga Kawa strives to empower businesses and brands to succeed in building a productive and positive environment at work and home. The team at Yoga Kawa believes that when yoga is practiced, the calm and rejuvenating energy can blossom and grow where one needs it the most. It is Yoga Kawa’s mission to connect high quality yoga teachers beyond yoga facilities, and integrate yoga into one’s daily routine.

Yoga Kawa can be contacted via phone at (647) 818-7418 or via email at info@yogakawa.com. For more information regarding the company or the various types of yoga services that they offer, visit their website.

Echo Wang
Yoga Kawa
+1 647-818-7418
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Alzheimer’s Disease (AD) explained in a new article by medical consultant Dr. Sohail Aman

Sohail Aman, MD, Maryland and Alabama

Sohail Aman, MD, Maryland and Alabama

Dr Sohail Aman, Medical Consultant in Maryland and Alabama

Dr Sohail Aman, Medical Consultant in Maryland and Alabama

Sohail Aman, MD, Maryland and Alabama

Sohail Aman, MD, Maryland and Alabama

Dr. Sohail Aman, Maryland and Alabama

Dr. Sohail Aman, Maryland and Alabama

Sohail Aman, MD, Maryland and Alabama

Sohail Aman, MD, Maryland and Alabama

Dr. Sohail Aman’s new article details the symptoms, causes and treatment for Alzheimer’s disease.

The complexity of the Alzheimer’s disease makes it untreatable and unpreventable. However, the medicines prescribed can be helpful in treating the individual symptoms…”

— Sohail Aman, MD, medical consultant

MOBILE, ALABAMA, UNITED STATES, June 30, 2019 /EINPresswire.com/ — Alzheimer’s disease, the most common cause of dementia, is a neurological disorder that occurs due to continuous degeneration of the brain cells. This incurable and irreversible disease hampers a patient’s cognitive and physical abilities. A person suffering from Alzheimer’s disease would eventually lose all memory and even cease to perform everyday tasks independently.

Medical Consultant Sohail Aman has published an article on this issue, which is available on his blog at https://sohailamanmd.home.blog/

As a progressive disease, it worsens with time. Alzheimer’s develops slowly in the beginning but gets fatal as it enters advanced stages and various associated health concerns like dehydration, infections start playing a role.

Signs and Symptoms

Some common signs and symptoms of Alzheimer’s disease are:

1. Memory Loss
Earlier symptoms may include forgetfulness or the inability to remember recent conversations or occurrences. The patient may also face difficulty in processing and communicating thoughts. As the memory loss worsens, the patient may keep on repeating something, forget appointments, unable to maintain his check books, and balance accounts, fail to identify people or objects, lose possessions or even get lost himself.

2. Sluggish Reasoning and Decision-Making Process
People suffering from Alzheimer’s find it particularly challenging to focus reason and multitask. With time, the patient’s decision-making skills will get poorer and the responses towards everyday issues will get slower.

3. Difficulty in Routine Activities
An Alzheimer’s patient struggles with everyday tasks. At an advanced stage, routine chores like eating, dressing and bathing may also become extremely arduous.

4. Behavioral Changes

A change in behavior is a significant symptom. The patient experiences mood swings, depression, insomnia, and aggressiveness. Social skills deteriorate and the patients feel surrounded by mistrust and delusions.

Causes

Definite causes of Alzheimer’s disease remain unknown to date. A mere 1% of patients have been observed to get the disease through genetics or their personal habits. A family history of Alzheimer’s disease increases the risk. Head traumas, unhealthy sleep patterns, and old age are also considered as possible causes in some studies. It has been found that the part of the brain responsible to retain and control memory, the hippocampus, undergoes neurological decay. A considerable amount of neurons die by the time the early signs of the disease start to manifest.
The disease spreads in different areas of the cerebral cortex. Two brain proteins are found to play a major role in causing the disease.

* Plaques
The remnants of larger proteins, Beta-amyloids, accumulate in the brain over time causing the decay of brain cells. The dead cells and bits of proteins combine to form plaque which impedes the functioning of the brain.
* Tangles
The neurological transport system is largely supported by Tau proteins. These special proteins restructure themselves as neuro-fibrillary tangles which are lethal to the cells and cause the transport system to collapse in an Alzheimer’s infected brain.

Treatment

The complexity of the Alzheimer’s disease makes it untreatable and unpreventable. However, the medicines prescribed can be helpful in treating the individual symptoms and decreasing the rate of cellular degeneration. Cholinesterase inhibitors are the type of drugs prescribed in early stages of the Alzheimer’s disease. According to the studies, these medicines help preserve a chemical called acetylcholine in the brain which prevents memory loss to some degree. Unfortunately, the inhibitors lose their effectiveness as the disease grows.

About Dr. Sohail Aman

Dr. Sohail Aman is a Consultant in Internal Medicine in Mobile, Alabama. He graduated from Medical School in 1992, and has completed several post-graduate training programs in internal medicine and a year in neurology training. He also holds a LMCC (Licentiate medical Council of Canada) certification and is a Fellow American College of Physicians, participates as a preceptor in medical Students clinical training program.

Website: https://SohailAman.com
Blog: https://sohailamanmd.home.blog/
Professional Profile: https://medicogazette.com/sohail-aman%2C-md-alabama
Professional Profile: https://hippocratesguild.com/sohail-aman%2C-md-alabama
News: https://hype.news/dr-sohail-aman-us/
LinkedIn: https://www.linkedin.com/in/sohail-aman-39317b45

Sohail Aman, MD
Sohail Aman, MD
+ +1 4432054040
email us here
Visit us on social media:
LinkedIn

UW Medicine: The good news on Alzheimer’s disease


Source: EIN Presswire

New study reveals biological toll on brain function of Holocaust survivors

5th Congress of the European Academy of Neurology

Stress of surviving the Holocaust has shown a lifelong and lasting negative impact on survivors’ brain structure, potentially impacting their offspring.

The impact of surviving the Holocaust on brain function is significant. We revealed substantial differences in the brain structures involved in the processing of emotion, memory and social cognition.”

— Professor Ivan Rektor

OSLO, NORWAY, June 30, 2019 /EINPresswire.com/ — Stress of surviving the Holocaust has shown a lifelong and lasting negative impact on survivors’ brain structure, as well as potentially impacting their offspring and grandchildren, a new study shows.

The novel research, presented today at the 5th European Academy of Neurology Congress, found that surviving the Holocaust had a life-long psychological and biological effect with grey matter reduction affecting the parts of their brain responsible for stress response, memory, motivation, emotion, learning, and behaviour.

Utilising MRI scanning, the study looked at the brain function of 56 people with an average age of 79-80, comparing 28 Holocaust survivors with 28 controls who do not have a personal or family history of the Holocaust. Survivors showed a significantly decreased volume of grey matter in the brain compared with controls of a similar age who had not been directly exposed via personal or family history to the Holocaust.

The study differentiated between survivors above and below the age of 12 years in 1945 and found that the reduction in grey matter was significantly more expressed in younger survivors, which may be attributed to the higher vulnerability to a stressful environment of the developing brain in childhood. In line with previous research, the study found a reduction of grey matter in areas of the brain associated with post-traumatic stress disorder (PTSD) in combat veterans and those suffering early-life stress experience. However, the research also showed that reductions in grey matter in other areas of the brain went far beyond what had previously been found in those suffering PTSD; with survivors suffering a higher level of stress but also higher levels of post-traumatic growth. Despite having suffered extreme stress the survivors reported that they were satisfied with their personal and professional life after the war.

The researchers are now investigating the impact of the Holocaust on survivors’ children and grandchildren, and early results in survivors’ children show reduced connectivity between structures of the brain involved in the processing of emotion and memory. Further research is set to identify biomarkers of stress resilience and post-traumatic growth and to determine whether transmission to offspring is based on behavioural and psychological factors or on genetic factors.

Commenting on their research findings, Professor Ivan Rektor, a neurologist from Brno, Czech Republic, explained, “After more than 70 years the impact of surviving the Holocaust on brain function is significant. We revealed substantial differences in the brain structures involved in the processing of emotion, memory and social cognition, in higher level of stress but also of post-traumatic growth between Holocaust survivors and controls. Early results show this is also the case in children of survivors too.”

“Our hope is that these findings and our ongoing research will allow us to understand more about the effect of these experiences in order to focus therapy to support survivors’ and their descendants’ resilience and growth. We may also reveal strategies that Holocaust survivors used to cope with trauma during their later lives and to pass on their experience to further generations”, added Professor Rektor.

ENDS

Notes to Editors:

Press Enquiries:

For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at press@ean.org or call +44 (0) 7732 499170.

Further Information:

For further information on the Holocaust, visit the Holocaust Memorial Day Trust: https://www.hmd.org.uk/learn-about-the-holocaust-and-genocides/the-holocaust/

About the Expert:

Professor Ivan Rektor is the Head of the Research Centre at the Centre for Neuroscience, Masaryk University.

EAN – The Home of Neurology:

The European Academy of Neurology (EAN) is Europe’s home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. This year, EAN celebrates its fifth year of fostering excellence in European neurology and will bring together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe.

In Oslo, Norway, from June 29 to July 2, there will be an exchange of knowledge and promotion of best practice, with a focus on the main theme of neuroinflammation. The EAN Congress will also cover all neurological diseases and disorders, including the big 7: epilepsy, stroke, headache, multiple sclerosis, dementia, movement disorders, neuromuscular disorders.

References:

1. Life-long effects of extreme stress on brain structures – a holocaust survivor MRI study. M. Fnaskova, P. Říha, I. Rektor, presented at the 5th Congress of International Neurology in Oslo.

Luke Paskins
European Academy of Neurology (EAN)
+44 7732 499170
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Early treatment is the key to beating Alzheimer’s disease in later life

5th Congress of the European Academy of Neurology

World-renowned neuroscientist Professor Bart De Strooper will deliver the ‘Brain Prize Lecture’ today at the 5th European Academy of Neurology (EAN) Congress.

Scientists need to shift their focus to the earlier stage of the disease and think about the cellular environment in which the disease develops”

— Professor Bart De Strooper

OSLO, NORWAY, June 29, 2019 /EINPresswire.com/ — World-renowned neuroscientist Professor Bart De Strooper will deliver the prestigious ‘Brain Prize Lecture’ today at the 5th European Academy of Neurology (EAN) Congress in Oslo, Norway, and outline why we need to intervene much earlier if we want to protect people against the symptoms of Alzheimer’s disease in later life.

This approach is based on decades of research on the causes of hereditary forms of Alzheimer’s disease and, unfortunately, disappointing clinical trial outcomes so far.

Over the past decades, Professor De Strooper has made important contributions to our understanding of the mechanisms of Alzheimer’s disease. This included uncovering that gene mutations in presenilin – part of the γ-secretase protein complex that ‘cuts’ other proteins into smaller pieces – lead to the production of abnormal amyloid to form plaques in the brains of people with Alzheimer’s disease.

His discoveries mark breakthrough findings in the dementia field, furthering the understanding of how Alzheimer’s disease may begin and provide potential new mechanisms to target with drug therapies in the future.

Professor De Strooper, Director of the UK Dementia Research Institute, London and group leader at the VIB-KU Leuven Center for Brain & Disease Research, Leuven, was awarded the Lundbeck Foundation Brain Prize for his work in this area last year and explained that understanding how these mutations drive dementia is important in developing new therapies. “We need to understand what is going on in the brain and how the brain operates while these changes occur”, he commented. “Treating amyloid at a very early stage could protect against symptoms later on and we must target these processes if we want to make the most effective treatments.”

The amyloid hypothesis works on the assumption that the accumulation of peptide amyloid-β plaques is the main cause of Alzheimer’s disease by triggering neurogenerative processes. This leads to the loss of memory and cognitive ability and has guided research into dementia treatments for the past 25 years.

Professor De Strooper commented, “For decades we have studied Alzheimer’s disease in its final stages. We now know that the disease process in the brain can start decades before the first symptoms arise. Studying the cognitive abnormalities in Alzheimer’s disease patients has indeed taught us a great deal about the disease, but we are always looking at an advanced stage or even post-mortem. You could compare this to studying cancer but only reviewing the metastatic disease, completely missing the stage where the disease actually originates and begins to spread. Needless to say, in both cases the chance of clinical success and making a meaningful change in treatment for patients, would be in those earlier stages.”

Trials for new Alzheimer’s drugs have, until now, often been tested in patients with advanced disease and it is therefore difficult to change the disease course. Professor De Strooper argues that we need to understand what happens before the plaques form in the cellular phase. “Scientists need to shift their focus to the earlier stage of the disease and think about the cellular environment in which the disease develops”, he observed.

Although budgets have been cut in dementia research, Professor De Strooper added there is still room for plenty of optimism due to the discoveries made on the neurodegenerative process. “Even though the situation is more complex than previously anticipated, if we compare the budgets and publication numbers in this disease area with those for cancer, it is simply not true that the success rate is exceptionally low. We just need to continue to invest heavily in new, innovative research to provide patients with optimal outcomes.”

ENDS

Notes to Editors:

Press Enquiries:
For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at press@ean.org or call +44 (0) 1444 811099.

About the Expert:

Professor Bart De Strooper is Director of the UK Dementia Research Institute (UK DRI) in London, UK, Professor of Alzheimer's Disease at University College London, UK, Professor of Molecular Medicine at the University of Leuven, Belgium) and Group Leader (and former Director) at the VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.

His scientific awards include a Brain Prize (2018), a European Grand Prix for Research (2018), and a Potamkin Prize (2002).

EAN – The Home of Neurology:

The European Academy of Neurology (EAN) is Europe’s home of neurology. Founded in 2014, through the merger of two European neurological societies, EAN represents the interests of more than 45,000 individual members and 47 national institutional members from across the continent. This year, EAN celebrates its fifth year of fostering excellence in European neurology and will bring together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe.

In Oslo, Norway, from June 29 to July 2, there will be an exchange of knowledge and promotion of best practice, with a focus on the main theme of neuroinflammation. The EAN Congress will also cover all neurological diseases and disorders, including the big 7: epilepsy, stroke, headache, multiple sclerosis, dementia, movement disorders, neuromuscular disorders.

References:

1. The Brain Prize Lecture: The prodromal, cellular phase of Alzheimer’s Disease: towards a novel understanding of the disorder. Presented on Sunday, 30 June, 2019, at The 5th European Academy of Neurology (EAN) Congress in Oslo, Norway

2. Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions: https://www.cell.com/cell/fulltext/S0092-8674(17)30811-5

Luke Paskins
European Academy of Neurology (EAN)
+44 1444 811099
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Precision in Healthcare to be Advanced by Immersive Learning in Middle East

UAE medical students set to learn thru immersion

UAE medical students set to learn thru immersion

3d organon munfarid 2

Virtual Reality allows positive developments in both performances and perceived capabilities of medical aspirants

3D Organon Anatomy Partner with Munfaird for Middle East

3D Organon Anatomy Partner with Munfaird for Middle East

Virtual Reality based Medical Learning by 3D Organon with Munfarid in Middle East

Virtual Reality based Medical Learning by 3D Organon with Munfarid in Middle East

How the aging medical learning will have a renovation through VR–Realistic Immersive Learning

The anticipation was real to save a critical patient, such tools help us practice the most difficult scenarios and be better prepared for real-life cases”

— Najla Naser, Student at Gulf Medical University

DUBAI, UNITED ARAB EMIRATES, June 29, 2019 /EINPresswire.com/ — As accelerated digitization has changed skill requirements, the workforce of tomorrow demands more active and ongoing approach to training and learning. Virtual Reality–the flag bearer of immersive learning has created an observant shift in the technological mainframe and has added new ways of communication, education and interaction. The whole idea of forging extended reality or replication of possible scenarios through VR is capable to simulate easy and practical learning.

IMMERSIVE LEARNING IS TRANSFORMING EDUCATION AND TRAINING PRACTICES ACROSS THE REGION
UAE has advanced in its operations to include immersive technologies in business, healthcare, and education, since 2015, in order to learn and derive the impact of VR in lowering the cost, reducing time to market, increase profits, and promote competitiveness. His Highness, Sheikh Mohammed bin Rashid Al Maktoum shares his thoughts on UAE’s innovation progress: “UAE has adopted innovation as an institutional approach and a culture of the society that aims at developing its human factor as well as government institutions, as part of its drive to build a sustainable future.”

UAE’s continuous strides in uplifting the economic power balance in the world today can be observed in market predictions announced by IDC or International Data Corporation, which claims that by 2020, the UAE's VR and AR market will jump to $ 6 Billion. Motivated by promising predictions, established UAE universities like Mohammed bin Rashid University are slowly fabricating radical and attested concepts of immersive learning into their course curriculums. Dr. Amer Ahmad Sharif, CEO of Dubai Healthcare City Authority-Education (DHCE) and Vice-Chancellor of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) quotes: “Our commitment to innovation and excellence only starts here. We’re inspiring a new generation of healthcare professionals who will impact the world with groundbreaking discoveries.” By placing students in an interactive learning environment, a smart transition from benign learning to practical learning will eventually educate them to adapt to any uncontrolled-real-life scenarios.

Dr. Sana Farid (X-Reality and AI Strategist, Munfarid) shared her views during an interview “There are infinite business applications of VR, from test drives to remote surgeries, but the most required and relevant potential of VR lies in healthcare, specifically in terms of exploration, learning forecasts and dissecting complex body engineering. By using virtual reality dynamic prototypes, the ability to depict certain organ movements becomes easier, which is a big breakthrough. ”

VR THROUGH ITS IMMERSIVE LEARNING HOLDS THE ABILITY TO DISSOLVE VARIOUS HEALTHCARE ISSUES
The advancements in Virtual Reality has enhanced scientific experiences and as a result, VR has unlocked the potential of improvising patient education, medical health treatments, fixing brain discordance, medical storytelling, drug visualization and improvised methods to learn body engineering. Virtual reality is proficient in assisting doctors and medical trainees in exploration which was earlier limited to rigid sources.

VR FOR MEDICAL AND NURSING EDUCATION
Virtual Reality allows positive developments in both performances and perceived capabilities of medical aspirants. OXFORD continues to support immersive learning methodologies and has readily adopted VR and AR (Augmented Reality) to provide its students with a new way to increase retention of information. Contributing to the global recognition and adoption of VR, and to best describe the applicability of VR and AR in education and research, the Middle East has progressed in its VR deployment strategy. Physiotherapy companies in UAE are already advancing their technological facilities by incorporating certain concepts of VR and AR for the rehabilitation of cerebral palsy, stroke and motor delay patients.

A student at Queen’s University in Canada, Samantha, comments on her VR training session: “The anticipation was real to save a critical patient, such tools help us practice the most difficult scenarios and be better prepared for real-life cases”. With students now being able to realistically simulate a wide range of clinical solutions, the probability of errors becomes less and the accomplishment rate of practical results gets accelerated.

MIDDLE EAST CONVERGES ITS INTEREST TO WISE AND WIDE ADOPTION OF IMMERSIVE LEARNING IN MEDICAL UNIVERSITIES
A prominent burden to VR in education is technological literacy. To bridge the gap between possibilities and learning, companies like 3D Organon in collaboration with Munfarid Global has introduced comprehensive learning programs in medical universities across the Middle East. Munfarid will focus on the implementation of programs in medical universities, so as medical trainees can visualize opportunities, derive readings and form new solutions, through this reformation in collaborative avatars of teaching atmosphere. By combining real and virtual environments, medical trainees can gain realistic readings and anticipate any patient’s life and death situations with circumstantial scenarios.

Surgical simulation can enhance the training process of medical aspirations as there is a broad disconnect in between combining cognitive and technical skills in the present models of simulation, adopted by a majority of medical universities.

Immersive Learning can become the essential bridge between healthcare practitioners and patients, as the virtual community creates a platform of wide exploration. All it requires is a dedicated implementation.

ABOUT 3D ORGANON:
3D Organon is the creative mogul behind the world’s first fully-featured VR anatomy atlas. The VR Anatomy allows medical aspirants to learn about the human body with full 3D female and male body models at the display which includes Connective, Skeletal, Muscular, Venous, Arterial, Nervous, Lymphatic, Respiratory, Heart, Digestive, Urinary, Endocrine, Reproductive, Integumentary, and Sensory organs.
3D Organon Website: https://www.3dorganon.com

ABOUT MUNFARID GLOBAL:
Munfarid focuses on providing intuitive and immersive learning opportunities to its clients across the Middle East. Creating strategic visions through benefits of ethos and innovative solutions, Munfarid has evolved as a regional and international participant in the global technological landscape.
Munfarid Website: https://munfarid.org/

ABOUT DR. SANA FARID:
Dr. Sana Farid, is a pioneer ARVR Strategist, a surgeon and Co-founder & CEO of Munfarid. She is a powerful, determined, and dedicated educational reformer who works towards implementing futuristic solutions for societal well-being. An acclaimed speaker, brilliant academician, and a simulation expert, Dr. Sana Farid has been featured amongst the top 100 women in Bahrain, Forbes, Entrepreneur, and Harvard Business Review in 2018. Her remarkable work is a highlight in the Middle East’s ARVR space, and now the world, as she contributes her valuable consultancy and insurgent technological solutions in supporting Governmental and non-Governmental initiatives. With her notable ambition in outlining the much-needed necessities of ARVR in the world, she has been credited extensively as a leader in MENA technological terrain. Her unparalleled dedication and consistency in uplifting healthcare and education standards with international contribution and implementation of innovative solutions in developing countries have inspired many. She has been awarded as an ambassador of women empowerment programs as well, which makes her the pinnacle of outstanding success.

Dr. Sana Farid
Munfarid Global
+971 55 361 3645
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Transformation of Healthcare through Immersive Technologies: by Dr. Sana Farid


Source: EIN Presswire

One in 10 people have ‘near-death’ experiences, according to new study

5th Congress of the European Academy of Neurology

Mystical near-death experiences where people report a range of spiritual and physical symptoms, affect around 10 per cent of people.

Our central finding is that we confirmed the association of near-death experiences with REM sleep intrusion.”

— Dr Daniel Kondziella

OSLO, NORWAY, June 29, 2019 /EINPresswire.com/ — Mystical near-death experiences where people report a range of spiritual and physical symptoms, including out-of-body sensations, seeing or hearing hallucinations, racing thoughts and time distortion, affect around 10 per cent of people, according to a new study that analysed participants from 35 countries.

These near-death experiences (NDEs) are equally as common in people who are not in imminent danger of death as in those who have experienced truly life-threatening situations such as heart attacks, car crashes, near drowning or combat situations.

The new findings were presented at the 5th European Academy of Neurology (EAN) Congress by researchers from the Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, Denmark, the Center for Stroke Research, Berlin, and the Norwegian University of Technology, Trondheim, Norway.

Experiences most frequently reported by participants in their study included: abnormal time perception (87 per cent), exceptional speed of thought (65 per cent), exceptionally vivid senses (63 per cent) and feeling separated from, or out of their body (53 per cent).

The study group who reported NDEs variously described feeling at total peace, having their ‘soul sucked out’, hearing angels singing, being aware they were outside their body, seeing their life flashing before them, and being in a dark tunnel before reaching a bright light. Others spoke of being aware of another’s presence before they went to sleep, or of a demon sitting on their chest while they lay paralysed unable to move.

The team recruited 1,034 lay people from 35 countries via a crowdsourcing platform online (to eliminate selection bias) and asked them if they’d ever had an NDE. If they answered ‘yes’, they were asked for more details, using a detailed questionnaire assessment tool called the Greyson Near-Death Experience Scale, which asks about 16 specific symptoms.
A total of 289 people reported an NDE, and 106 of those reached a threshold of 7 on the Greyson NDE Scale, (which confirms a true NDE). Some 55 per cent perceived the NDE as truly life-threatening and 45 per cent as not truly life-threatening.

Far from being a pleasant experience associated with feelings of peacefulness and wellbeing, as some previous studies have reported, the new study found a much higher rate of people reporting their NDE as unpleasant. Overall, of all the people who claimed an NDE, 73 per cent said it was unpleasant and only 27 per cent said it was pleasant. However, in those with a score of 7 or above on the Greyson NDE Scale (a confirmed NDE), this changed to 53 per cent reporting a pleasant experience and 14 per cent an unpleasant one.

Based on insight gained from previous studies, the researchers found an association between NDEs and Rapid Eye Movement (REM) sleep intrusion into wakefulness. REM sleep is a phase of the sleep cycle where the eyes move rapidly, the brain is as active as when someone is awake, dreaming is more vivid, and most people experience a state of temporary paralysis, as the brain send a signal to the spinal cord to stop the arms and legs moving. When REM sleep intrudes into wakefulness, some people report visual and auditory hallucinations and other symptoms such as sleep paralysis, where they feel conscious but cannot move.

REM sleep intrusion on wakefulness was found to be more common in people with scores of 7 or above on the Greyson NDE Scale (47 per cent) than in people with scores of 6 or below (26 per cent), or in those below the threshold with no such experiences (14 per cent).

Lead researcher Dr Daniel Kondziella, a neurologist at the University of Copenhagen, said, “Our central finding is that we confirmed the association of near-death experiences with REM sleep intrusion. Although association is not causality, identifying the physiological mechanisms behind REM sleep intrusion into wakefulness might advance our understanding of near-death experiences.”

Dr Kondziella said that the 10 per cent prevalence figure of NDE was higher than in previous studies conducted in Australia (8 per cent) and Germany (4 per cent). He said this could be explained by the fact they had been conducted on cardiac arrest survivors rather than unprimed lay people, as in this study.

Dr Kondziella said the study replicated the findings of an earlier study by Nelson et al in 20062 that had been criticised for selectional bias, but the new study addressed those potential flaws by recruiting via a crowdsourcing platform.

ENDS

Press Enquiries:

For further information or to speak to an expert, please contact Luke Paskins or Hannah Murray at press@ean.org or call +44 (0) 7732 499170.

Selected reports from participants with an experience that reached the threshold of ≥7 points on the 3 Greyson NDE scale to qualify as a near-death experience:

Female, 37 years, childbirth: “I felt like I just died, and I went to heaven. I heard voices, and I was sure I would not come back to my life. It was weird. I could not control my body.”

Female, 32 years, near-drowning: “I nearly drowned when I was around 8 years old. I felt total peace. Twenty years later I can still remember how I felt. It was an amazing feeling.”

About the Expert:
Dr Daniel Kondziella is a neurologist at the University of Copenhagen, Denmark.

EAN – The Home of Neurology:
The European Academy of Neurology (EAN) is Europe’s home of neurology. This year, EAN celebrates its fifth year of fostering excellence in European neurology and will bring together more than 6,000 neurologists and related scientists to the biggest general neurology conference in Europe.

References:

1. Prevalence of near-death experiences in people with and without REM sleep intrusion. Presented at the 5th European Academy of Neurology (EAN) Congress on Saturday, 29 June, 2019.

2. Nelson KR et al; ‘Does the arousal experience contribute to near death experience? Neurology 2006, April 11; 66(7); 1003-9 https://www.ncbi.nlm.nih.gov/pubmed/16606911

Luke Paskins
European Academy of Neurology (EAN)
+44 7732 499170
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire